Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Wood

Showing results (21-30 of 341) with videos related to

Pageof 35
Sort By:
European Urology|May 30, 2012
Words of wisdom. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialPatrick A Kenney, Christopher G Wood
The Journal of Urology|September 26, 2017
Editorial CommentJose A Karam, Christopher G Wood
Current Opinion in Urology|August 15, 2006
Staging refinements in renal cell carcinomaGalen E Howard, Christopher G Wood
Nature Clinical Practice. Urology|February 11, 2009
Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?Stephen H Culp, Christopher G Wood
Annals of Translational Medicine|September 21, 2020
Editorial Commentary: <i>Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study</i>Mary E Westerman, Christopher G Wood
European Urology|February 8, 2011
The dark side of targeted therapyJose A Karam, Christopher G Wood
The Urologic Clinics of North America|April 11, 2012
Integration of surgery and systemic therapy for renal cell carcinomaPatrick A Kenney, Christopher G Wood
European Urology|March 14, 2012
The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated?Jose A Karam, Christopher G Wood
The Journal of Urology|January 20, 2010
Editorial commentJose A Karam, Christopher G Wood
Seminars in Oncology|October 19, 2006
Adjuvant therapy for renal cell carcinomaKenneth M Jacobsohn, Christopher G Wood
Pageof 35

Showing results (21-30 of 341) with videos related to

Sort By:
Pageof 35
European Urology|May 30, 2012
Words of wisdom. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialPatrick A Kenney, Christopher G Wood
The Journal of Urology|September 26, 2017
Editorial CommentJose A Karam, Christopher G Wood
Current Opinion in Urology|August 15, 2006
Staging refinements in renal cell carcinomaGalen E Howard, Christopher G Wood
Nature Clinical Practice. Urology|February 11, 2009
Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?Stephen H Culp, Christopher G Wood
Annals of Translational Medicine|September 21, 2020
Editorial Commentary: <i>Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study</i>Mary E Westerman, Christopher G Wood
European Urology|February 8, 2011
The dark side of targeted therapyJose A Karam, Christopher G Wood
The Urologic Clinics of North America|April 11, 2012
Integration of surgery and systemic therapy for renal cell carcinomaPatrick A Kenney, Christopher G Wood
European Urology|March 14, 2012
The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated?Jose A Karam, Christopher G Wood
The Journal of Urology|January 20, 2010
Editorial commentJose A Karam, Christopher G Wood
Seminars in Oncology|October 19, 2006
Adjuvant therapy for renal cell carcinomaKenneth M Jacobsohn, Christopher G Wood
Pageof 35